Active Biotech AB Interim Report, January - September 2009
(Thomson Reuters ONE) - * Laquinimod -- new data presented at ECTRIMS* 57-57 -- exploratory clinical trial in progress* RhuDex(TM) -- clinical development to continue following feedback from UK MHRA* ANYARA -- complete Phase I data published* TASQ -- complete Phase I data published* ISI -- project proceeding according to plan* Net sales of SEK 7.7 M (8.8)* Operating loss of SEK 164.6 M (loss: 167.0)* Loss after tax of SEK 165.1 M (loss: 162.0)* Loss per share for the period amounted to SEK 2.90 (loss: 3.30)* Number of shares at the end of the period, thousands (incl. warrants): 64,943 For further information, please contact: Tomas Leanderson President and CEO Tel: +46 (0)46-19 20 95 Göran Forsberg VP Investor Relations & Business Development Tel: +46 (0)46-19 11 54 Hans Kolam CFO Tel: +46 (0)46-19 20 44 Active Biotech AB (Corp. Reg. No. 556223-9227) PO Box 724, SE-220 07 Lund Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00 This report is also available at www.activebiotech.com http://hugin.info/1002/R/1352670/327332.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Bereitgestellt von Benutzer: hugin
" alt="Osisko Concludes SGF Financing Agreement for $75 M
Datum: 05.11.2009 - 08:32 Uhr
Sprache: Deutsch
News-ID 7948
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 362 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim Report, January - September 2009"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
